EVTCY - Evotec SE

Other OTC - Other OTC Delayed Price. Currency in USD
51.86
-0.45 (-0.86%)
As of 12:45PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close52.31
Open51.86
Bid0.00 x 0
Ask0.00 x 0
Day's Range51.86 - 51.86
52 Week Range33.40 - 57.57
Volume341
Avg. Volume858
Market Cap3.861B
Beta (3Y Monthly)1.44
PE Ratio (TTM)53.03
EPS (TTM)0.98
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Catalyst Pharma (CPRX) Rides on Successful Launch of Firdapse
    Zacks23 hours ago

    Catalyst Pharma (CPRX) Rides on Successful Launch of Firdapse

    Catalyst Pharma (CPRX) gains on the successful launch of Firdapse. The company is looking to develop drug for additional indications.

  • Catalent Acquires Gene Therapy Leader Paragon Bioservices
    Zacks2 days ago

    Catalent Acquires Gene Therapy Leader Paragon Bioservices

    Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.

  • ACCESSWIRE3 days ago

    Evotec SE to Acquire Just Biotherapeutics, Inc.

    HAMBURG, GERMANY / ACCESSWIRE / May 20, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announced today the signing of a definitive agreement under which Evotec ...

  • ACCESSWIRE3 days ago

    Evotec Jump-Starts Biologics with Acquisition of Just Biotherapeutics

    EVOTEC'S OFFERING OF INTEGRATED SOLUTIONS EXTENDED TO BIOLOGICS ADDITION OF LONGSTANDING BIOLOGICS EXPERTISE BASED ON KEY TALENTS, INNOVATIVE ML (MACHINE LEARNING) DRIVEN TECHNOLOGIES AND SOPHISTICATED ...

  • ACCESSWIRE8 days ago

    Evotec To Attend Upcoming Investor Conferences

    HAMBURG, GERMANY / ACCESSWIRE / May 15, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following ...

  • ACCESSWIRE10 days ago

    Evotec SE Reports First Quarter 2019 Results And Provides Corporate Update

    - VERY GOOD START WITH 27% INCREASE IN GROUP REVENUES AND STRONG UNDERLYING INDICATIONS FOR FY 2019 - GOOD PROGRESS IN EXISTING CO-OWNED PORTFOLIO AND EXPANDING WITH NEW ALLIANCES - WEBCAST AND CONFERENCE ...

  • ACCESSWIRE16 days ago

    Evotec SE to Report First Quarter 2019 Results on 14 May 2019

    HAMBURG, GERMANY / ACCESSWIRE / May 7, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will report its financial results for the first quarter of 2019 on Tuesday, 14 May ...

  • Evotec's (ETR:EVT) Wonderful 545% Share Price Increase Shows How Capitalism Can Build Wealth
    Simply Wall St.18 days ago

    Evotec's (ETR:EVT) Wonderful 545% Share Price Increase Shows How Capitalism Can Build Wealth

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! For us, stock picking is in large part the hunt for the truly magnificent stocks. Mistakes...

  • ACCESSWIRElast month

    Evotec Completes Repayment Of EUR 140 M Acquisition Loan

    EUR 140 M BRIDGE LOAN WAS DRAWN TO SECURE EVOTEC'S VALUE CHAIN EXPANSION BY SUCCESSFUL ACQUISITION OF APTUIT IN AUGUST 2017 STRONG OPERATIONAL CASH FLOW ENABLES FULL REPAYMENT WITHIN LESS THAN TWO YEARS ...

  • ACCESSWIRElast month

    Evotec And Indivumed Announce Strategic Drug Discovery Collaboration On Precision Medicine For Colorectal Cancer

    HAMBURG, GERMANY / ACCESSWIRE / April 11, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Indivumed GmbH announced today that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer ("CRC"). The collaboration, which runs for an initial term of two years, will combine Evotec's proprietary bioinformatics analysis platform "PanHunter" as well as its small molecule and antibody discovery platforms with the CRC cohort of Indivumed's true multi-omics cancer database "IndivuType".

  • ACCESSWIRE2 months ago

    EVOTEC AG COMPLETES CONVERSION INTO EVOTEC SE

    HAMBURG, GERMANY / ACCESSWIRE / April 1, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has completed its conversion into a company under European ...

  • Could Evotec AG's (ETR:EVT) Investor Composition Influence The Stock Price?
    Simply Wall St.2 months ago

    Could Evotec AG's (ETR:EVT) Investor Composition Influence The Stock Price?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! A look at the shareholders of Evotec AG (ETR:EVT) can tell us which group is most powerful. Large companies usually have...

  • ACCESSWIRE2 months ago

    EVOTEC AG FISCAL YEAR 2018 RESULTS: ACCELERATED GROWTH AND STRONG LONG-TERM OUTLOOK

    - EXCELLENCE IN SCIENCE, PARTNERED DRUG DISCOVERY & DEVELOPMENT, ACQUISITIONS, AND UNIQUE PLATFORM TECHNOLOGIES LEAD TO STRONG GROWTH MOMENTUM - STRONG FINANCIAL RESULTS: 42% INCREASE IN GROUP REVENUES, ...

  • ACCESSWIRE2 months ago

    Evotec And The Mark Foundation For Cancer Research Announce Strategic Collaboration In Immuno-Oncology

    HAMBURG, GERMANY / ACCESSWIRE / March 26, 2019 / Evotec AG (EVT.DE), (MDAX/TecDAX, ISIN: DE0005664809) and The Mark Foundation for Cancer Research today announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics in oncology. The collaboration, for an initial period of two years, is based on Evotec's new proprietary drug discovery platform TargetAlloMod, which is focused on disrupting cell signalling via a novel mechanism of action. The Mark Foundation's focus of funding highly innovative oncology research and drug discovery is extremely well aligned with Evotec's mission to exploit novel platforms for the generation of first-in-class and clearly differentiated therapies.

  • ACCESSWIRE2 months ago

    Evotec AG to Report Fiscal Year 2018 Results on 28 March 2019

    HAMBURG, GERMANY / ACCESSWIRE / March 21, 2019 / Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will report its financial results for 2018 on Thursday, 28 March 2019. The Company ...

  • ACCESSWIRE2 months ago

    Evotec And GARDP Announce New Partnership To Discover Novel Antibiotics

    COLLABORATION EXPLORES OPPORTUNITIES TO SET UP ANTIBIOTIC DISCOVERY AND DEVELOPMENT PLATFORM AND ESTABLISH A JOINT PIPELINE OF NOVEL ANTIBIOTIC ASSETS DISCOVERY EFFORTS WILL FOCUS ON WORLD HEALTH ORGANIZATION ...

  • ACCESSWIRE3 months ago

    Evotec to Attend Upcoming Investor Conferences

    HAMBURG, GERMANY / ACCESSWIRE / March 7, 2019 / Evotec AG (FSE: EVT, OTC PINK: EVTCY, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following ...

  • ACCESSWIRE3 months ago

    Evotec And Galapagos Enter Into Collaboration In The Field Of Fibrosis

    COLLABORATION COMPRISES LICENCE AGREEMENT FOR A PROGRAMME DEVELOPED BY EVOTEC AS WELL AS ITS DRUG DISCOVERY CAPABILITIES EVOTEC RECEIVES UNDISCLOSED UPFRONT PAYMENT AND IS ELIGIBLE FOR POTENTIAL MILESTONES ...

  • ACCESSWIRE4 months ago

    Evotec Receives Milestone Payment for Start of Phase II Clinical Trial

    EVOTEC'S PARTNER, SECOND GENOME, BEGINS A PHASE II CLINICAL TRIAL FOR NASH WITH LICENSED MOLECULE, SGM-1019 HAMBURG, GERMANY / ACCESSWIRE / January 24, 2019 / Evotec AG (Frankfurt Stock Exchange: EVT, ...

  • Is Evotec AG’s (ETR:EVT) 16% Better Than Average?
    Simply Wall St.4 months ago

    Is Evotec AG’s (ETR:EVT) 16% Better Than Average?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...

  • ACCESSWIRE4 months ago

    Evotec Reaches Important Scientific Achievement Within IPSC-Based Collaboration With Celgene

    HAMBURG, GERMANY / ACCESSWIRE / January 8, 2019 / Evotec AG (EVT.DE) (EVT.DE) (OTC PINK: EVTCY), (MDAX/TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene Corporation ("Celgene") has reached another important scientific achievement, resulting in Celgene designating a programme and triggering a payment of $ 14.0 m to Evotec. This scientific achievement was the advancement of a programme into the lead optimisation stage developed from Evotec's compound library using its induced pluripotent stem cell ("iPSC")-based screening platform.

  • ACCESSWIRE4 months ago

    Evotec Invests in Financing Round Of Exscientia

    $ 26 M FINANCING ROUND (SERIES B) INCLUDES CELGENE, GT HEALTHCARE CAPITAL PARTNERS AND EVOTEC PROCEEDS TO ACCELERATE SCALING AS LEADING AI DRUG DISCOVERY COMPANY HAMBURG, GERMANY / ACCESSWIRE / January ...

  • Why Evotec AG’s (ETR:EVT) High P/E Ratio Isn’t Necessarily A Bad Thing
    Simply Wall St.5 months ago

    Why Evotec AG’s (ETR:EVT) High P/E Ratio Isn’t Necessarily A Bad Thing

    The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll look at Evotec AG's (ETR:EVT) P/E ratio and reflect on what Read More...

  • Evotec AG (ETR:EVT): What Are The Future Prospects?
    Simply Wall St.6 months ago

    Evotec AG (ETR:EVT): What Are The Future Prospects?

    Since Evotec AG (ETR:EVT) released its earnings in June 2018, analyst consensus outlook appear cautiously subdued, with profits predicted to rise by 19% next year compared with the higher past Read More...

  • Is Evotec AG’s (ETR:EVT) CEO Paid Enough To Stay Motivated?
    Simply Wall St.6 months ago

    Is Evotec AG’s (ETR:EVT) CEO Paid Enough To Stay Motivated?

    In 2013 Werner Lanthaler was appointed CEO of Evotec AG (ETR:EVT). First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth that the Read More...